drugset / Trial / NCT00124956
Doxorubicin Pharmacokinetic (PK) Study
Phase 1/2
Withdrawn
Boston Children's Hospital
Elizabeth Glaser Pediatric AIDS Foundation · collabGlaser Pediatric Research Network · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This protocol is designed to obtain detailed information on the impact of body composition on the pharmacokinetic behavior of doxorubicin after a single intravenous dose in children 21 years of age or younger. There is no efficacy component. Approximately 9 children will be enrolled at Children's Hospital Boston. The information gained from this study could be very important in developing dosing strategies for doxorubicin in the obese patient population.
Timeline
- Start
- 2003-06
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | — | Intravenous |